Chandar Abboy, M.D.
7208 Bellera Court
Charlotte NC 28277
Cell: 864-381-1383
cabboymd@yahoo.com

Summary: Triple Board-Certified physician with experience in inpatient and outpatient medicine. Board Certified in Pulmonary Medicine, Critical Care Medicine, and Sleep Medicine. Over 15+ years of clinical experience from fellowship.

Board Certifications

Internal Medicine – (Active) – Initially certified in 2005 and re-certified in 2015, deactivated 12/31/2025
Pulmonary Medicine – (Active) – Initially certified 2008 and re-certified in 2018
Critical Care Medicine – (Active) – Initially certified 2009 and re-certified in 2019
Sleep Medicine – (Active) – Initially certified in 2013 and re-certified in 2023

Education

Fellowship	Winthrop University Hospital now NYU Langone Hospital - Long Island, Mineola, NY Pulmonary/Critical Care July 2006 – June 2009
Residency	The Christ Hospital, Cincinnati, OH Internal Medicine Residency Program July 2002 – June 2005
Medical School	Madras Medical College, India MBBS – August 1995 to March 2001
College/University	University of California, Irvine Bachelor of Science – Biological Sciences Minor in History September 1991-June 1995

Professional Experience

June 2022 to Present	Care Access - Decentralized Clinical Trials Principal Investigator
Jan 2021 to Present	Expert Witness

Apr 2019 to Present	Locum Tenens
	Location: Prisma Health Baptist Parkridge Hospital, Irmo, South Carolina Mcleod Regional Medical Center, Florence, South Carolina Vidant Health, Greenville, North Carolina Cape Fear Valley Hospital, Fayetteville, North Carolina Trident Medical Center, North Charleston, South Carolina Providence Health, Columbia, South Carolina Coliseum Medical Center, Macon, Georgia Piedmont Medical Center, Rock Hill, South Carolina Frye Medical Center, Hickory, North Carolina St. Francis Hospital, Columbus, Georgia Novant Health Presbyterian Medical Center, Charlotte, North Carolina AdventHealth Hendersonville, Hendersonville, North Carolina UNC Southeastern, Lumberton North Carolina MUSC Health Lancaster Medical Center, Lancaster, North Carolina Summerville Medical Center, Summerville, South Carolina
Aug 2009 to Apr 2019	Physician – Upstate Lung and Critical Care Specialists, P.C. Spartanburg, Gaffney, and Pelham in South Carolina (Inpatient and Out-patient practicing pulmonary, sleep medicine and critical care medicine in hospital ICUs.); Principal Investigator for Vitalink - Greenville.
July 2005 to June 2006	Tri - State Pulmonary – Cincinnati, OH Worked seeing pulmonary inpatients and outpatients and managing long term acute care patients.

Medical Licensure

MD 31600 – South Carolina (Active)
2011-01582 – North Carolina (Active)
85100 - Georgia (Active)
AFE88857 - California (Active)
31936 - West Virginia (Active)
15414A - Wyoming (Active)
MD-51009 - Iowa (Active)
MD2023-0407 - New Mexico (Active)
01090072A - Indiana (Active)
32412 - Mississippi (Active)
40172 - Oklahoma (Active)
PT 20277 - North Dakota (Active)
82797-20 - Wisconsin (Active)

36.171246 - Illinois (Active)
42.0017953 - Vermont (Active)
26054 - Nevada (Active)
CP898 - Nebraska (Active)
MED-PHYS-COM-LIC-143383 - Montana (Active)
C1-0027341 - Delaware (Active)
MD221270 - Oregan (Active)

Honors and Recognition

Resident Advisor, Ernest Amory Codman Award in Multiple Organization Category by JCAHO for the Greater Cincinnati Patient Safety ICU Collaborative, Cincinnati, Ohio -2006

Administrative Posts

Chief of Staff, Spartanburg Center for Restorative Care – 2012-2017
Sleep Co-Director, Providence Health Sleep Disorders Center, 2017-2018

Hospice Experience

Medical Director, Agape Hospice – 2012-2018
Medical Director, Providence Care Hospice, 2018-2019

Clinical Research Experience

June 2022 - Present	Decentralized Clinical Trials Principal Investigator for Care Access
Dec 2009 – April 2019	Clinical Investigator, Vitalink Research – Greenville
2008 – 2009	Sub-Investigator, Winthrop University Hospital Clinical Trials, Mineola, NY

CLINICAL RESEARCH STUDIES

ALZHEIMER'S DISEASE	A study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease. 15T-MC-AACM. Eli Lilly(TRAILBLAZER-ALZ 3). 2022.
	A study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline. J1G-MC-LAKI. (TRAILRUNNER-ALZ 3). Eli Lilly. 2024
	A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD). I5T-MC-AACU. LY888888. Eli Lilly. 2025

OBESITY	A Phase 3b, Randomized, Double Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity. J1I-MC-GZQB. (TRIUMPH-6). Eli Lilly. 2024.
	A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants without Type 2 Diabetes Who have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial (TRIUMPH - 9). J1I-MC-GZQL. Eli Lilly. 2025
CARDIOVASCULAR	A Multicenter, Cross-Sectional Study to Characterize the Distrubiton of Lipoprotein (a) Levels among Patients with Documented History of Atherosclerotic Cardiovascular Disease. Amgen. 2022.
	A Multicenter, Randomized, Double-blind, Placebo-Controlled, 8-Week Study to Evaluate the Safety and Efficacy of Nebivolol and Valsartan Given as a Fixed-Dose Combination in Patients with Stage 1 or 2 Essential Hypertension. Forest Research Institute Protocol NAC-MD-01 (2012 – 2013)
DIABETES	Post Market Surveillance Registry for the Endogenex System. Endogenex 1419 (PULSE). Endogenex. 2025.
	Continued Access the Endogenex System for Participants in the ReCET Pivotal Study. Endogenex 1421 (ACCESS). Endogenex 2025.
ASTHMA/COPD	A multicentre, Randomized, Double-Blind, Placebo-Controlled, Dose Finding, Parallel Group, Phase 2 study an anti-TSLP Antibody (GSK5784283) in Adults aged 18-75 years of age with Uncontrolled asthma. GlaxoSmithKline 223125. 2024.
	A Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma. GlaxoSmithKline, Protocol SASI 15359 (2012-2015).
	Phase II - A 12 week Randomized. Multiple-Dose, Double-Blind, Placebo-Controlled. Parallel Group Study to Evaluate Nebulized Fluticasone Propionate (FP) Dose Response in Adult Subjects with Partly Controlled and Uncontrolled Asthma. Dey Pharma, Inc. Protocol 191-091 (2012 • 2014)
	A Phase Ill, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma Who are on Inhaled Corticosteroids and a Second Controller Medication. Genetech, Protocol GB27864 (2012. 2013)
	A Randomized, Double-Blind. Placebo Controlled, 3-Way Crossover Incomplete Block Study To Assess The Dose Responsiveness Of Exhaled

Nitric Oxide To Advair@ Diskus@ Inhaler in Adult Asthmatic Subjects. MylanlChiltem Protocol MgrOOO-1002 (2012-2013)

A Phase 2, Double-blind, Placebo-controlled. Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects with Asthma Inadequately Controlled by Corticosteroids. KaloBios Phamaceutica!s, Inc. Protocol KB003-04 (2012 — 2013)

Bb.lnd 8464: A Phase lib Study To Investigate The Treatment Sparing Effects Of Aerovant™ (Aer 001 Inhalation Powder In Asthma Patients Not Fully Controlled On Current Therapy)Aerovance, Protocol Pddt2007/Aero 01 Dpi2b (2008-2010)

ACHIEVE, A randomized, double-blind, placebo-controlled. incomplete unbalanced, crossover study to assess the efficacy and safety of three doses of formoterol fumarate in Pressair compared with Perforomist Inhalation Solution (20 and 40ug open-label) in moderate to severe COPD patients with reversible airway disease. AstraZeneca, Protocol D6571C00002 (2016-2017)

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vitanterol on Exercise Endurance Time in Subjects with COPD. GlaxoSmithKline, Protocol 201317 (2015-2016)

Randomized. Placebo-Controlled Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment with Nebulized SUN-101 in Patient with COPD: GOLDEN-3 (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer). Sunovion, Protocol SUN101-301 (2015-2016)

A Randomized, Double Blind, Chronic Dosing (24 Weeks), Placebo Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003. PT005, and PTOOI in Subjects with Moderate to Very Severe COPD, Compared with Placebo. Pearl Therapeutics, Inc.. Protocol PT003014-01 (2015-2016)

A Phase 3, 12 week, Randomized, Double-Blind Placebo-Controlled Parallel-Group Study of Nebulized TD-4208 in with Chronic Obstructive Pulmonary Disease. Theravance. Protocol TD-4208-0126 (2015-2016)

A Dose-finding Study of batefenterol (GSK961081) via Dry Powder Inhaler in with COPD. GlaxoSmithKline, Protocol 201012 (2015-2016)

A Randomized, Phase 111b. Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24 hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003, Open Label Spiriva@ Respimat@ Tiotropium Bromide) as an Active Control, and Placebo MDI, Pearl Therapeutics, Inc.. Protocol PT003011 (2015-2016)

A Randomized. Phase 111b, Two period, Two treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24 hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003 and Placebo MDI. Peari Therapeutics, Inct Protocol PT023012 (2015-2016)

A Phase 111B, 6.Month, Double blind, Double-dummy, Randomized, Parallel-group Multicenter Exacerbation Study of Symbicort@ pMDl 160/4.5 pg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 pg x 2 Inhalations Twice-daily in COPD Patient[k] AstraZeneca, Protocol D589UC00001 (2014-2016)

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of Long Term Use of Perforomist@(fomoterol fumarate) Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease (COPD)V DEY Pharma, Inc., Protocol 201-085 (2012-2016)

A Randomized, Open-Label, Active-Controlled , Parallel-Group, Multicenter. Long-Term Safety Study Trial Of Treatnent With Nebulized Sun-101 In Patients With Copd: Golden-5 (Glycopyrrolate For Obstructive Lung Disease Via Electronic Nebulizer). Sunovion, Protocol Sunl 01-303 (2015-2016)

The Flagship Study: A 12-Week Phase li Study To Evaluate The Efficacy And Safety Of Aqx-1125 Following Exacerbations In Patients With Chronic Obstructive Pulmonary Disease (Copd) By Targeting The Shipl Pathway, Aquinox, Protocol Aqx.1125-202 (20142015)

A 12-week multi-center, randomized, double-blind, placebo controlled study to assess the efficacy and safety of NVA237 in stable COPD patients. Novartis Pharmaceuticals. Protocol CNVA237A2317 (2013-2014)

A Dose-Range Finding Study Of Sun-101 In With Moderate To Severe Copd: Golden 6 (Glycopyrrolate For Obstructive Lung Disease Via Electronic Nebulizer). Sunovion Protocol Sun101-201 (2013-2014)

A 12-week treatment, multi-center. randomized, double blind, parallel-group. placebo and active controlled study to assess the efficacy, safety, and tolerability of QVAI 49 (indacaterol maleate I glycopyrronium bromide) in COPD patients with moderate to severe airflow limitation. Novartis Pharmaceuticals Protocol CQVA149A2337 (2012-2014)

A 12-week treatment, multi-center. randomized, double blind, parallel group, placebo and active controlled study to assess the efficacy, safety, and tolerability of QVA149 (indacaterol mateate / glycopyrronium bromide) in COPD patients with moderate to severe airflow limitation. Novartis Pharmaceuticals Protocol CQVA149A2336 (2012-2014)

	A study to compare the addition of umeclidinium bromide (UMEC) to auticasone furoate (FF)/vilanterol (VI), with placebo plus FFNI in with Chronic Obstructive Pulmonary Disease (COPD) - study 2 GlaxoSmithK-line Protocol 200110 (2013 - 2014)
	A randomized, double-blind, placebo-controlled, parallel group study to determine the effect of 12 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 pg, 515 pg) delivered by the Respimat@ Inhaler, on exercise endurance time during constant work rate cycle ergometry in patients with Chronic Obstructive Pulmonary Disease (COPD) [Torracto™] Boehringer Ingelheim Protocol 1237.15 (2012-2014)
COPD	A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies. LTS18133. Sanofi (2024-2025)
	Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety and tolerability of SAR440340/ REGN3500/itepekimab (Anti-IL 33 mAb) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). EFC16819, Aerify 2. Sanofi.
	Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety and tolerability of SAR440340/ REGN3500/itepekimab (Anti-IL 33 mAb) in patients with moderate to severe chronic obstructive pulmonary disease (COPD). EFC16750, Aerify 1. Sanofi.
	A randomized, double-blind, 5 treatment arms, 4-period, incomplete cross-over study to determine the effect of 6 weeks treatment of orally inhaled tiotropium + olodaterol fixed dose combination (FDC) (2.5 / 5 µg; and 5 / 5 µg) (delivered by the Respimat® Inhaler) compared with tiotropium (5 µg), olodaterol (5 µg) and placebo (delivered by the Respimat® Inhaler) on lung hyperinflation and exercise endurance time during constant work rate cycle ergometry in patients with Chronic Obstructive Pulmonary Disease (COPD) [MORACTO™ 1] Boehringer Ingelheim Protocol 1237.13 (2012-2014)
	A randomized, double-blind, parallel group study to assess the efficacy and safety of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination (2.5 µg/5 µg; 5 µg/5 µg) (delivered by the Respimat® Inhaler) compared with the individual components (2.5 µg and 5 µg tiotropium, 5 µg olodaterol) (delivered by the
	Respimat® Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD) [TOnado™ 2] Boehringer Ingelheim Protocol 1237.6 (2011-2013)

A randomized, multi-center, double-blind, double-dummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12 weeks in subjects with COPD. GlaxoSmithKline Protocol DB2114951 (2013 – 2013)

Protocol Number and Title: 1222.52 A randomized, double-blind, parallel group study to assess the efficacy and safety of 12 weeks of once daily, orally inhaled, co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium 18 µg (delivered by the HandiHaler®) compared to once daily, orally inhaled, co-administration of placebo (delivered by the Respimat® Inhaler) and tiotropium18 µg (delivered by the HandiHaler®) in patients with Chronic Obstructive Pulmonary Disease (COPD) (ANHELTO™1) Boehringer Ingelheim Protocol 1222.52 (2012-2013)

A Large Simple Safety Study of Arformoterol Tartrate Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease. Sepracore/ Sunovion Protocol 091-080 (2010-2013)

A 52-week, Double-Blind, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Effect of Roflumilast 500 µg on Exacerbation Rate in Subjects with Chronic Obstructive Pulmonary Disease (COPD) Treated with a Fixed Dose Combination of Long-Acting Beta Agonist and Inhaled Corticosteroid (LABA/ICS) Forest Research Institute, Inc. ROF-MD-07 (2011-2012)

An exercise endurance study to evaluate the effects of treatment of COPD patients with a dual bronchodilator: GSK573719/GW642444 GlaxoSmithKline Protocol DB2114417 (2011-2012)

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects with Chronic Obstructive Pulmonary Disease (COPD). GlaxoSmithKline Protocol DB2113361 (2011-2012)

A multicenter trial comparing the efficacy and safety of GSK573719/ GW642444 with GW642444 and with tiotropium over 24 weeks in subjects with COPD GlaxoSmithKline Protocol DB2113360 (2011-2012)

A randomized, double blind, placebo controlled, incomplete block, crossover, dose ranging study to evaluate the dose response of GSK573719 administered once or twice daily over 7 days in patients with COPD. GlaxoSmithKline Protocol AC4115321 (2011)

An eight-week, multicenter, double-blind, randomized, parallel group study of fluticasone propionate/salmeterol DISKUS combination product (FSC) 250/50 mcg twice daily plus tiotropium 18 mcg daily versus placebo DISKUS twice daily plus tiotropium 18 mcg daily on exercise time and

physiological parameters in subjects with Chronic Obstructive Pulmonary Disease (COPD) GlaxoSmithKline Protocol ADC113877 (2011)

"A 12-week, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess the Pharmacodynamic Response of Fluticasone Propionate in Fixed-Dose Combination with Formoterol Fumarate in Subjects with COPD" DEY Protocol 191-090 (2010-2011)

A Randomized, Multiple-Dose, Crossover Study Characterizing the Pharmacodynamic Profiles of Formoterol Fumarate Inhalation Solution and Formoterol Dry Powder Inhaler in Subjects with Stable Chronic Obstructive Pulmonary Disease DEY Protocol 191-089 (2010)

An eight-week, multicenter, double-blind, randomized, parallel group study of fluticasone propionate/salmeterol DISKUS combination product (FSC) 250/50 mcg twice daily plus tiotropium 18 mcg daily versus placebo DISKUS twice daily plus tiotropium 18 mcg daily on exercise time and physiological parameters in subjects with Chronic Obstructive Pulmonary Disease (COPD) GlaxoSmithKline ADC113877 (2010-2011)

A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS™) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS™) on the Rate of Exacerbations of Chronic Obstructive Pulmonary Disease (COPD) Following Hospitalization GlaxoSmithKline Protocol ADC113874 (2010)

Validation of a New Shortness of Breath with Daily Activities Questionnaire in patients with Chronic Obstructive Pulmonary Disease GlaxoSmithKline Protocol ASQ112989 (2010)

Randomized, double-blind, double-dummy, placebo-controlled, 4-way cross-over study to determine the 24-hour FEV1-time profiles of orally inhaled BI 1744 CL (5 µg [2 actuations of 2.5 µg] and 10 µg [2 actuations of 5 µg]), administered once daily with the Respimat® Inhaler, and orally inhaled Foradil® (12 µg), administered twice daily with the Aerolizer® Inhaler, after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease (COPD) Boehringer-Ingelheim Protocol 1222.24 (2009-2010)

GOUT

A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Febuxostat Compared to Febuxostat Alone at Lowering Serum Uric Acid and Resolving Tophi in Subjects with Tophaceous Gout. Ardea Biosciences, Protocol RDEA 594-304 (2013-2014)

INFLUENZA

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intramuscular Peramivir in Subjects with Uncomplicated Acute Influenza. BioCryst Pharmaceuticals, Inc. Protocol BCX1812-311 *(2010)*

PRESENTATIONS AND PUBLICATIONS

"To Scope or Not to Scope": Ventilator-Associated Pneumonia. Pneumonia Trends; Clinical Pulmonary Medicine. 14(4): 240, July 2007, Abboy, Chandar, MD; Spiegler, Peter MD, FCCP, 2007

"Platypnea - Orthodeoxia Syndrome" Case Review with Dr. Sunil Dama, Published in Consultant. 2005